• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    12/18/24 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRDA alert in real time by email

    BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).

    A live webcast will be available on the Presentations portion of Entrada's Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event.

    About Entrada Therapeutics

    Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The Company's lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45 and 50 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

    For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

    Investor and Media Contact

    Caileigh Dougherty

    Head of Investor Relations & Corporate Communications

    [email protected]



    Primary Logo

    Get the next $TRDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRDA

    DatePrice TargetRatingAnalyst
    12/6/2024$29.00Buy
    ROTH MKM
    1/5/2024$22.00Outperform
    Oppenheimer
    4/3/2023$25.00Buy
    H.C. Wainwright
    11/24/2021Outperform
    Evercore ISI Group
    11/23/2021Outperform
    Cowen & Co.
    11/23/2021$29.00Neutral
    Goldman Sachs
    More analyst ratings